Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
An announcement from MAIA Biotechnology, Inc. ( (MAIA) ) is now available.
On February 4, 2025, MAIA Biotechnology announced positive updates from its Phase 2 THIO-101 trial for advanced non-small cell lung cancer. The trial showed a significant median overall survival of 16.9 months, suggesting a strong advantage over standard chemotherapy treatments. This development enhances MAIA’s regulatory strategy and could expedite FDA approval, marking a potential breakthrough for patients with limited treatment options.
More about MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer. The company is particularly involved in creating first-in-class drugs aimed at treating non-small cell lung cancer (NSCLC) by targeting cancer telomeres.
YTD Price Performance: -4.31%
Average Trading Volume: 333,496
Technical Sentiment Consensus Rating: Buy
Find detailed analytics on MAIA stock on TipRanks’ Stock Analysis page.